Abstract
SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 499-518 |
| Number of pages | 20 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 18 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Novel approaches for the treatment of small cell lung cancer. / Wakelee, Heather; Kelly, Karen.
In: Hematology/Oncology Clinics of North America, Vol. 18, No. 2, 04.2004, p. 499-518.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel approaches for the treatment of small cell lung cancer
AU - Wakelee, Heather
AU - Kelly, Karen
PY - 2004/4
Y1 - 2004/4
N2 - SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.
AB - SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.
UR - http://www.scopus.com/inward/record.url?scp=1942503367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1942503367&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2004.01.001
DO - 10.1016/j.hoc.2004.01.001
M3 - Article
C2 - 15094184
AN - SCOPUS:1942503367
VL - 18
SP - 499
EP - 518
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 2
ER -